Literature DB >> 11192960

Efficacy of salbutamol via Easyhaler unaffected by low inspiratory flow.

T Koskela1, K Malmström, U Sairanen, S Peltola, J Keski-Karhu, M Silvasti.   

Abstract

The fine particle dose delivered via dry powder inhalers (DPIs) is often affected by the inspiratory flow rate generated during inhalation. This has clinical implications, since the fine particle dose determines the amount of drug reaching the lungs. With Easyhaler DPI the fine particle dose remains relatively constant over the range of inspiratory flow rates from 30-60 l min(-1). The aim of this study was to confirm that clinical efficacy is maintained even at low flow rates by comparing the bronchodilating effect of salbutamol (100 microg) delivered via Easyhaler at a target inspiratory flow of 30 l min(-1) with the same dose of salbutamol via pressurised metered-dose inhaler (pMDI) plus spacer. This was a double-blind, randomized, cross-over study with double-dummy technique. Twenty-one paediatric and adult asthmatic patients completed the study, which was conducted over 2 study days. The main outcome parameter was forced expiratory volume in 1 sec (FEV1). The patients were trained to generate a low peak inspiratory flow rate (PIFR) of 30 l min(-1), and the actual PIFR through Easyhaler was recorded. The average PIFR through Easyhaler was 28.7 l min(-1). The difference in the maximum value of FEV1 (FEV1max) between the treatments after drug inhalation was 0.01 l. The mean of FEV1max was 2.67 l after pMDI plus spacer compared to 2.69 l after Easyhaler. Improvements in FEV1 were clinically significant. No significant differences between treatments were found. A reasonably low inspiratory flow rate through Easyhaler produces an equivalent improvement in lung function to a correctly used pMDI plus spacer. Hence, Easyhaler can be used with confidence in patients who may have difficulty in generating a high inspiratory flow rate, such as children and the elderly.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11192960     DOI: 10.1053/rmed.2000.0959

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  4 in total

Review 1.  Closer to an 'ideal inhaler' with the Easyhaler: an innovative dry powder inhaler.

Authors:  Henry Chrystyn
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

2.  Inspiratory flows through dry powder inhaler in chronic obstructive pulmonary disease: age and gender rather than severity matters.

Authors:  L Pekka Malmberg; Paula Rytilä; Pertti Happonen; Tari Haahtela
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-08-09

3.  Evaluation of in vitro and in vivo flow rate dependency of budesonide/formoterol Easyhaler(®).

Authors:  L Pekka Malmberg; Mark L Everard; Jussi Haikarainen; Satu Lähelmä
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2014-06-30       Impact factor: 2.849

4.  Switching patients from other inhaled corticosteroid devices to the Easyhaler(®): historical, matched-cohort study of real-life asthma patients.

Authors:  David Price; Vicky Thomas; Julie von Ziegenweidt; Shuna Gould; Catherine Hutton; Christine King
Journal:  J Asthma Allergy       Date:  2014-04-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.